Some of the observed outcomes here were in line with the CheckMate-141 trial, since 18% (24/132) of the study population experienced an objective response favouring those with PD-L1-positive and/or HPV-positive tumours, median PFS and OS times were 2 and 8 months, respectively, and grade 3–4 treatment-related side effects occurred in 9% of enrolled patients [33]. Here, CD274 is linked to neoplasm.